In these two decades more cytokines and their receptors arise involving hemopoiesis, not only colony stimulating factors, int erleukins and growth factors but also chemokines etc. Some novel cytokines wer e discovered...In these two decades more cytokines and their receptors arise involving hemopoiesis, not only colony stimulating factors, int erleukins and growth factors but also chemokines etc. Some novel cytokines wer e discovered as the ligand of “orphan receptor” e.g. FL and KL, which played c ritical role for proliferation of stem cell and progenitors. On the other hand, novel cytokine or cytokine receptor were encoded by some viruses- “virokine” o r “viroceptor” also reported in last decade.展开更多
本文对几种造血细胞因子,包括重组人粒/巨噬细胞集落刺激因子(Recombinant human granulocyte-macrophage colony-stimulating factor,rhGM-CSF)、重组人粒细胞集落刺激因子(Recombinant human granulocytecolony-stimulating factor,rh...本文对几种造血细胞因子,包括重组人粒/巨噬细胞集落刺激因子(Recombinant human granulocyte-macrophage colony-stimulating factor,rhGM-CSF)、重组人粒细胞集落刺激因子(Recombinant human granulocytecolony-stimulating factor,rhG-CSF)、重组人红细胞生成素(Recombinant human erythropoietin,rhEPP),干扰素(Interferon,IFN)、白介素-2(interleukin-2)与LAK细胞(Lymphokine activated killer cell)的临床应用机理、适应症、毒副作用,根据我们几年来的实践体会,结合国内外文献复习作了介绍。近年细胞因子的研究进展迅速,新的细胞因子不断被发现并推向临床,对已用于临床的细胞因子的适应症、用药时机、剂量和毒副作用的防治等临床经验也越来越丰富。用细胞因子治疗一些过去被认为难治的疾病已展示出可喜的前景,但目前也还存在一些问题,如价格昂贵、市场品种繁多、效应不一等等,给临床应用带来困难。展开更多
文摘In these two decades more cytokines and their receptors arise involving hemopoiesis, not only colony stimulating factors, int erleukins and growth factors but also chemokines etc. Some novel cytokines wer e discovered as the ligand of “orphan receptor” e.g. FL and KL, which played c ritical role for proliferation of stem cell and progenitors. On the other hand, novel cytokine or cytokine receptor were encoded by some viruses- “virokine” o r “viroceptor” also reported in last decade.
文摘本文对几种造血细胞因子,包括重组人粒/巨噬细胞集落刺激因子(Recombinant human granulocyte-macrophage colony-stimulating factor,rhGM-CSF)、重组人粒细胞集落刺激因子(Recombinant human granulocytecolony-stimulating factor,rhG-CSF)、重组人红细胞生成素(Recombinant human erythropoietin,rhEPP),干扰素(Interferon,IFN)、白介素-2(interleukin-2)与LAK细胞(Lymphokine activated killer cell)的临床应用机理、适应症、毒副作用,根据我们几年来的实践体会,结合国内外文献复习作了介绍。近年细胞因子的研究进展迅速,新的细胞因子不断被发现并推向临床,对已用于临床的细胞因子的适应症、用药时机、剂量和毒副作用的防治等临床经验也越来越丰富。用细胞因子治疗一些过去被认为难治的疾病已展示出可喜的前景,但目前也还存在一些问题,如价格昂贵、市场品种繁多、效应不一等等,给临床应用带来困难。
